| - |
Blinatumomab |
Blincyto® |
As monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (BCP-ALL) in first or second complete remission with minimal residual disease greater than or equal to 0.1%. |
Rapid Review complete |
23rd September 2019 |
 |
| - |
Blinatumomab |
Blincyto® |
Treatment of paediatric patients aged 1 year and older with Philadelphia chromosome negative B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation |
Rapid Review complete |
30th January 2019 |
|
| 21031 |
Blinatumomab |
Blincyto® |
Treatment of paediatric patients (aged 1 year plus) with high-risk first-relapsed Ph- CD19+ B-precursor acute lymphoblastic leukaemia as part of consolidation therapy. |
Rapid Review complete |
3rd August 2021 |
|
| - |
Boceprevir |
Victrelis® |
As add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1. |
NCPE Assessment Process Complete |
17th January 2012 |
|
| - |
Bosentan |
Tracleer® |
Treatment pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO Functional Class (FC) III and WHO FC II. It is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease. |
Rapid Review complete |
8th July 2014 |
|
| - |
Bosutinib |
Bosulif® |
Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. |
Rapid Review complete |
25th September 2013 |
|
| - |
Brentuximab vedotin |
Adcetris® |
Treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and is also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma. |
NCPE Assessment Process Complete |
11th April 2014 |
|
| - |
Brentuximab vedotin |
Adcetris® |
Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy (license extension). |
Rapid Review complete |
6th March 2018 |
|
| 19058 |
Brentuximab vedotin |
Adcetris® |
Treatment of adult patients with CD30+ Hodgkin’s lymphoma at increased risk of relapse or progression following autologous stem cell transplant. |
NCPE Assessment Process Complete |
22nd October 2021 |
|
| 21010 |
Brentuximab vedotin |
Adcetris® |
In combination with cyclophosphamide [C], doxorubicin [H] and prednisone [P] (CHP) in combination for use in adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL). |
Rapid Review complete |
23rd April 2021 |
|
| 23045 |
Brexucabtagene Autoleucel |
Tecartus® |
Adults 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia |
NCPE assessment ongoing |
18th September 2024 |
|
| - |
Brigatinib |
Alunbrig® |
As monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib. |
Rapid Review complete |
11th December 2018 |
|
| 20031 |
Brigatinib |
Alunbrig® |
As monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK-inhibitor. |
Rapid Review complete |
6th August 2020 |
|
| - |
Brimonidine |
Mirvaso® |
Treatment of facial erythema of rosacea in adult patients. |
Rapid Review complete |
7th May 2014 |
|
| - |
Brivaracetam |
Briviact® |
As adjunctive therapy in the treatment of partial-onset seizures (POS) with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. |
Rapid Review complete |
22nd March 2016 |
|
| - |
Brodalumab |
Kyntheum® |
Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. |
Rapid Review complete |
29th August 2017 |
|
| 20009 |
Brolucizumab |
Beovu® |
Treatment of neovascular (wet) age-related macular degeneration. |
Rapid Review complete |
7th April 2020 |
|
| - |
Budesonide |
Jorveza® |
Treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age). |
Rapid Review complete |
26th May 2020 |
|
| 24014 |
Budesonide |
Jorveza® |
For the treatment of eosinophilic oesophagitis in adults (older than 18 years of age). |
Rapid Review complete |
7th June 2024 |
|
| 22067 |
Bulevirtide |
Hepcludex® |
Chronic hepatitis delta (CHD) infection in plasma (or serum) HDV RNA-positive adult patients with compensated liver disease. |
NCPE Assessment Process Complete |
22nd February 2024 |
|
| 22037 |
Buprenorphine/Naloxone |
Zubsolv® |
As substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who agreed to be treated for addiction. |
Rapid Review complete |
21st June 2022 |
|
| 22056 |
Buprenorphine |
Buvidal® |
Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over. |
Rapid Review complete |
5th June 2024 |
|
| - |
Buprenorphine/Naloxone |
Suboxone® |
Management of opiate addiction |
NCPE Assessment Process Complete |
22nd May 2014 |
|
| - |
Burosumab |
Crysvita® |
Treatment of X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons. |
NCPE Assessment Process Complete |
12th March 2020 |
|
| 23005 |
Burosumab |
Crysvita® |
Burosumab (Crysvita®) is indicated for X-linked hypophosphataemia in adult patients. |
NCPE Assessment Process Complete |
1st August 2024 |
|
| - |
C1inhibitor (human) |
Cinryze® |
Treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE). Routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment |
Rapid Review complete |
15th November 2012 |
|
| - |
Cabazitaxel |
Jevtana® |
Treatment of patients with hormone-refractory metastatic prostate cancer previously treated with docetaxel-containing treatment regimen. |
NCPE Assessment process complete |
13th March 2012 |
|
| 21026 |
Cabotegravir/Rilpivirine |
Vocabria®/Rekambys® |
HIV-1 infection in adults who are virologically suppressed on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class. |
Rapid Review complete |
21st July 2021 |
|
| - |
Cabozantinib |
Cabometyx® |
Treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. |
NCPE Assessment process complete |
4th July 2018 |
|
| 22018 |
Cabozantinib/Nivolumab |
Cabometyx®/Opdivo® |
First-line treatment of advanced renal cell carcinoma in adults. |
Awaiting full HTA submission from Applicant |
14th August 2024 |
|
| - |
Cabozantinib |
Cometriq® |
Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. For patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision. |
Rapid Review complete |
13th August 2014 |
|
| 22063 |
Calcifediol monohydrate |
Dnord® |
Treatment of vitamin D deficiency (i.e., 25(OH)D levels <25 nmol/L) in adults, for the prevention of vitamin D deficiency in adults with identified risks such as in patients with malabsorption syndrome, chronic kidney disease mineral and bone disorder (CKD-MBD) or other identified risks, and as an adjuvant for the specific treatment of osteoporosis in patients with vitamin D deficiency or at risk of vitamin D deficiency. |
Rapid Review complete |
13th October 2022 |
|
| - |
Calcipotriol/Betamethasone dipropionate |
Enstilar® |
For the topical treatment of psoriasis vulgaris in adults |
Rapid review complete |
22nd June 2016 |
|
| - |
Camellia sinensis, folium (green tea leaf) |
Catephen® |
Cutaneous treatment of external genital and perianal warts (condylomataacuminata) in immunocompetent patients from the age of 18 years. |
Rapid Review complete |
10th July 2015 |
|
| - |
Canagliflozin |
Invokana® |
Treatment of type 2 diabetes as monotherapy or add-on combination therapy to other glucose-lowering medicinal products including insulin |
NCPE Assessment Process complete |
29th August 2014 |
|
| 20004 |
Cannabidiol |
Epidyolex® |
As adjunctive therapy of seizures associated with Dravet Syndrome in conjunction with clobazam, for patients two years of age and older. |
NCPE Assessment Process complete |
8th March 2021 |
|
| 20005 |
Cannabidiol |
Epidyolex® |
As adjunctive therapy of seizures associated with Lennox-Gastaut Syndrome in conjunction with clobazam, for patients two years of age and older. |
NCPE Assessment Process complete |
8th March 2021 |
|
| 21024 |
Cannabidiol |
Epidyolex® |
As adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older. |
Rapid Review complete |
8th July 2021 |
|
| 24015 |
Capivasertib |
Truqap® |
Capivasertib (Truqap®) is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. |
Awaiting full HTA submission from Applicant |
5th September 2024 |
|
| 22013 |
Caplacizumab |
Cablivi® |
Treatment of adults and adolescents aged 12 years and older weighing at least 40 kg experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression. |
Rapid Review complete |
31st March 2022 |
|
| 22049 |
Capmatinib |
Tabrecta® |
Advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. |
Rapid Review complete |
28th February 2024 |
|
| - |
Capsaicin |
Qutenza® |
Peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain. |
Rapid Review complete |
2nd July 2012 |
|
| 20054 |
Carfilzomib (in combination with daratumumab and dexamethasone) |
Kyprolis® |
In combination with daratumumab and dexamethasone (CAR+DAR+DEX) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
NCPE Assessment Process Complete |
3rd July 2024 |
|
| - |
Carfilzomib (in combination with dexamethasone) |
Kyprolis® |
For the treatment of adult patients with multiple myeloma who have received at least one prior therapy |
Rapid Review complete |
19th March 2019 |
|
| - |
Carfilzomib (in combination with lenalidomide and dexamethasone) |
Kyprolis® |
For the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
NCPE Assessment process complete |
19th October 2016 |
|
| 22035 |
Carglumic acid |
Ucedane® |
Treatment of hyperammonaemia due to N-acetyl-glutamate synthase (NAGS) primary deficiency. |
Rapid Review complete |
21st June 2022 |
|
| - |
Cariprazine |
Reagila® |
For the treatment of schizophrenia in adult patients. |
Rapid Review complete |
19th December 2018 |
|
| 21067 |
Casirivimab/imdevimab |
Ronapreve® |
For the treatment and prevention of COVID-19. |
Rapid Review complete |
1st February 2022 |
|
| - |
Catumazomab |
Removab® |
For the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible. |
Rapid Review complete |
6th September 2011 |
|
| 22003 |
Cefiderocol |
Fetcroja® |
For the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. Consideration should be given to official guidance on the appropriate use of antibacterial agents. |
Rapid Review complete |
5th June 2024 |
|
